Last reviewed · How we verify
Narcan Nasal Product
At a glance
| Generic name | Narcan Nasal Product |
|---|---|
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Role of the Opioid System in Placebo Effects on Pain and Social Rejection (EARLY_PHASE1)
- Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD (NA)
- An Evaluation of a Social Network Intervention for Primary and Secondary Prevention of Opioid Overdoses (NA)
- Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) (NA)
- Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications
- Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital (PHASE3)
- Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder (PHASE2)
- A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |